| Butler Center For Rehabilitation And Healthcare | |
| 416 S High Street, Butler, Missouri 64730 | |
| (660) 679-6158 | |
| Name | Butler Center For Rehabilitation And Healthcare |
|---|---|
| Location | 416 S High Street, Butler, Missouri |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 98 |
| Occupancy Rate | 58.67% |
| Medicare ID (CCN) | 265275 |
| Legal Business Name | Breezy Operations Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1598137887 |
| Organization Name | BREEZY MEADOWS, LLC |
| Address | 416 S High St, Butler, MO 64730 |
| Phone Number | 660-679-6158 |
News Archive
Advanced Cancer Therapeutics (ACT) has announced the signing of two new collaborative agreements that will advance development of the Company's novel human papillomavirus (HPV) vaccine program.
A new computational model that simulates bone metastasis of prostate cancer has the potential to rapidly assess experimental therapy outcomes and help develop personalized medicine for patients with this disease, according to data published in Cancer Research, a journal of the American Association for Cancer Research.
It has so far not been proven that long-acting insulin analogues (LAIAs) have an advantage over conventional human insulin in the treatment of patients with type 2 diabetes.
Dipexium Pharmaceuticals, Inc., a late-stage pharmaceutical company focused on the development and commercialization of Locilex (pexiganan cream 0.8%), and research collaborators, JMI Laboratories, announced that new Locilex microbiology data were presented at the American Society for Microbiology's Interscience Conference of Antimicrobial Agents and Chemotherapy and International Society of Chemotherapy's International Congress of Chemotherapy and Infection (ICAAC/ICC 2015) scientific conference in San Diego, California, September 17-21, 2015.
› Verified 2 days ago
| NPI Number | 1619669645 |
| Organization Name | BUTLER OPERATOR LLC |
| Address | 416 S High St, Butler, MO 64730 |
| Phone Number | 660-679-6158 |
News Archive
Advanced Cancer Therapeutics (ACT) has announced the signing of two new collaborative agreements that will advance development of the Company's novel human papillomavirus (HPV) vaccine program.
A new computational model that simulates bone metastasis of prostate cancer has the potential to rapidly assess experimental therapy outcomes and help develop personalized medicine for patients with this disease, according to data published in Cancer Research, a journal of the American Association for Cancer Research.
It has so far not been proven that long-acting insulin analogues (LAIAs) have an advantage over conventional human insulin in the treatment of patients with type 2 diabetes.
Dipexium Pharmaceuticals, Inc., a late-stage pharmaceutical company focused on the development and commercialization of Locilex (pexiganan cream 0.8%), and research collaborators, JMI Laboratories, announced that new Locilex microbiology data were presented at the American Society for Microbiology's Interscience Conference of Antimicrobial Agents and Chemotherapy and International Society of Chemotherapy's International Congress of Chemotherapy and Infection (ICAAC/ICC 2015) scientific conference in San Diego, California, September 17-21, 2015.
› Verified 2 days ago
| NPI Number | 1851830384 |
| Organization Name | BREEZY OPERATIONS LLC |
| Doing Business As | BUTLER CENTER FOR REHABILITATION AND HEALTHCARE |
| Address | 416 S High St, Butler, MO 64730 |
| Phone Number | 660-679-6158 |
News Archive
Advanced Cancer Therapeutics (ACT) has announced the signing of two new collaborative agreements that will advance development of the Company's novel human papillomavirus (HPV) vaccine program.
A new computational model that simulates bone metastasis of prostate cancer has the potential to rapidly assess experimental therapy outcomes and help develop personalized medicine for patients with this disease, according to data published in Cancer Research, a journal of the American Association for Cancer Research.
It has so far not been proven that long-acting insulin analogues (LAIAs) have an advantage over conventional human insulin in the treatment of patients with type 2 diabetes.
Dipexium Pharmaceuticals, Inc., a late-stage pharmaceutical company focused on the development and commercialization of Locilex (pexiganan cream 0.8%), and research collaborators, JMI Laboratories, announced that new Locilex microbiology data were presented at the American Society for Microbiology's Interscience Conference of Antimicrobial Agents and Chemotherapy and International Society of Chemotherapy's International Congress of Chemotherapy and Infection (ICAAC/ICC 2015) scientific conference in San Diego, California, September 17-21, 2015.
› Verified 2 days ago
| NPI Number | 1891736690 |
| Organization Name | HEARTLAND-WILLOW LANE OF BUTLER MO LLC |
| Doing Business As | HEARTLAND OF WILLOW LANE |
| Address | 416 S High St, Butler, MO 64730 |
| Phone Number | 660-679-6158 |
News Archive
Advanced Cancer Therapeutics (ACT) has announced the signing of two new collaborative agreements that will advance development of the Company's novel human papillomavirus (HPV) vaccine program.
A new computational model that simulates bone metastasis of prostate cancer has the potential to rapidly assess experimental therapy outcomes and help develop personalized medicine for patients with this disease, according to data published in Cancer Research, a journal of the American Association for Cancer Research.
It has so far not been proven that long-acting insulin analogues (LAIAs) have an advantage over conventional human insulin in the treatment of patients with type 2 diabetes.
Dipexium Pharmaceuticals, Inc., a late-stage pharmaceutical company focused on the development and commercialization of Locilex (pexiganan cream 0.8%), and research collaborators, JMI Laboratories, announced that new Locilex microbiology data were presented at the American Society for Microbiology's Interscience Conference of Antimicrobial Agents and Chemotherapy and International Society of Chemotherapy's International Congress of Chemotherapy and Infection (ICAAC/ICC 2015) scientific conference in San Diego, California, September 17-21, 2015.
› Verified 2 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Advanced Cancer Therapeutics (ACT) has announced the signing of two new collaborative agreements that will advance development of the Company's novel human papillomavirus (HPV) vaccine program.
A new computational model that simulates bone metastasis of prostate cancer has the potential to rapidly assess experimental therapy outcomes and help develop personalized medicine for patients with this disease, according to data published in Cancer Research, a journal of the American Association for Cancer Research.
It has so far not been proven that long-acting insulin analogues (LAIAs) have an advantage over conventional human insulin in the treatment of patients with type 2 diabetes.
Dipexium Pharmaceuticals, Inc., a late-stage pharmaceutical company focused on the development and commercialization of Locilex (pexiganan cream 0.8%), and research collaborators, JMI Laboratories, announced that new Locilex microbiology data were presented at the American Society for Microbiology's Interscience Conference of Antimicrobial Agents and Chemotherapy and International Society of Chemotherapy's International Congress of Chemotherapy and Infection (ICAAC/ICC 2015) scientific conference in San Diego, California, September 17-21, 2015.
› Verified 2 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 1 |
| Total Amount of Fines in Dollars | $7660 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 1 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 14 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 3.16 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 20.43 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 3.62 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 4.4 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 1.17 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 3.7 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 20.51 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 92.64 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 0 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 17.18 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 37.58 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 13.54 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 98.52 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 86.28 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 74.8 | 82.93 |
News Archive
Advanced Cancer Therapeutics (ACT) has announced the signing of two new collaborative agreements that will advance development of the Company's novel human papillomavirus (HPV) vaccine program.
A new computational model that simulates bone metastasis of prostate cancer has the potential to rapidly assess experimental therapy outcomes and help develop personalized medicine for patients with this disease, according to data published in Cancer Research, a journal of the American Association for Cancer Research.
It has so far not been proven that long-acting insulin analogues (LAIAs) have an advantage over conventional human insulin in the treatment of patients with type 2 diabetes.
Dipexium Pharmaceuticals, Inc., a late-stage pharmaceutical company focused on the development and commercialization of Locilex (pexiganan cream 0.8%), and research collaborators, JMI Laboratories, announced that new Locilex microbiology data were presented at the American Society for Microbiology's Interscience Conference of Antimicrobial Agents and Chemotherapy and International Society of Chemotherapy's International Congress of Chemotherapy and Infection (ICAAC/ICC 2015) scientific conference in San Diego, California, September 17-21, 2015.
› Verified 2 days ago
Butler Center For Rehabilitation And Healthcare Location: 416 S High Street, Butler, Missouri 64730 Phone: (660) 679-6158 | |